Commitments and Contingencies	6 Months Ended
Jun. 30, 2026
Commitments and Contingencies
Commitments and Contingencies	5. Commitments and Contingencies Litigation In the normal course of business, the Company is from time to time named as a party to legal claims and actions. The Company records a loss contingency reserve for a legal proceeding when the potential loss is considered probable and can be reasonably estimated. The Company has not recorded any amounts for loss contingencies as of June 30, 2026. On June 17, 2024, Steven M. Fruchtman informed the Board of his intent to resign from his positions as President and Chief Scientific Officer, Oncology and indicated to the Company that Dr. Fruchtman believed his resignation to be for “good reason” under the terms of his employment agreement and his expectation of compensation commensurate therewith and in connection with a change in control. The Board accepted Dr. Fruchtman’s resignation effective immediately but disagreed with the characterization of the events set forth in the letter. The claims were submitted to arbitration for resolution, and arbitration proceedings began in June 2026 with the American Arbitration Association. Following an evidentiary hearing held in June 2026, the arbitrator issued a Decision and Award on July 14, 2026. The arbitrator denied Mr. Fruchtman's claims for breach of contract and breach of the implied covenant of good faith and fair dealing, finding that Mr. Fruchtman did not have "Good Reason" to resign because his removal from the Board of Directors and the CEO position did not constitute a material breach of his employment agreements, and because he failed to prove that control of the Company changed immediately following the merger within the meaning of the applicable "Change in Control" definition. Accordingly, the arbitrator found that Mr. Fruchtman was not entitled to severance payments. In addition, the arbitrator denied Mr. Fruchtman's motion for discovery sanctions, finding that the Company's conduct did not warrant sanctions. As a result, the Company does not expect to incur any liability, including any severance or change in control payments, in connection with that matter, and no loss contingency has been recorded with respect to this matter as of June 30, 2026. Contingent Value Rights The Company issued CVRs to common stockholders as of April 15, 2024, and may be obligated to make future distributions to such CVR holders in connection with entering into strategic arrangements related to its oncology programs and/or future royalty payments related to the successful commercialization of such programs.

Commitments and Contingencies

6 Months Ended

Jun. 30, 2026

5. Commitments and Contingencies

Litigation

In the normal course of business, the Company is from time to time named as a party to legal claims and actions. The Company records a loss contingency reserve for a legal proceeding when the potential loss is considered probable and can be reasonably estimated. The Company has not recorded any amounts for loss contingencies as of June 30, 2026.

On June 17, 2024, Steven M. Fruchtman informed the Board of his intent to resign from his positions as President and Chief Scientific Officer, Oncology and indicated to the Company that Dr. Fruchtman believed his resignation to be for “good reason” under the terms of his employment agreement and his expectation of compensation commensurate therewith and in connection with a change in control. The Board accepted Dr. Fruchtman’s resignation effective immediately but disagreed with the characterization of the events set forth in the letter. The claims were submitted to arbitration for resolution, and arbitration proceedings began in June 2026 with the American Arbitration Association. Following an evidentiary hearing held in June 2026, the arbitrator issued a Decision and Award on July 14, 2026. The arbitrator denied Mr. Fruchtman's claims for breach of contract and breach of the implied covenant of good faith and fair dealing, finding that Mr. Fruchtman did not have "Good Reason" to resign because his removal from the Board of Directors and the CEO position did not constitute a material breach of his employment agreements, and because he failed to prove

that control of the Company changed immediately following the merger within the meaning of the applicable "Change in Control" definition. Accordingly, the arbitrator found that Mr. Fruchtman was not entitled to severance payments. In addition, the arbitrator denied Mr. Fruchtman's motion for discovery sanctions, finding that the Company's conduct did not warrant sanctions. As a result, the Company does not expect to incur any liability, including any severance or change in control payments, in connection with that matter, and no loss contingency has been recorded with respect to this matter as of June 30, 2026.

Contingent Value Rights

The Company issued CVRs to common stockholders as of April 15, 2024, and may be obligated to make future distributions to such CVR holders in connection with entering into strategic arrangements related to its oncology programs and/or future royalty payments related to the successful commercialization of such programs.